<DOC>
	<DOCNO>NCT03106779</DOCNO>
	<brief_summary>The purpose pivotal study compare efficacy ABL001 bosutinib treatment patient CML-CP previously treat minimum two prior ATP-binding site TKIs BCR-ABL ratio ≥ 1 % IS screening .</brief_summary>
	<brief_title>Study Efficacy CML-CP Patients Treated With ABL001 Versus Bosutinib , Previously Treated With 2 More TKIs</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Male female patient diagnosis CMLCP ≥ 18 year age Patients must meet following laboratory value screen visit : &lt; 15 % blast peripheral blood bone marrow &lt; 30 % blast plus promyelocytes peripheral blood bone marrow &lt; 20 % basophils peripheral blood ≥ 50 x 109/L ( ≥ 50,000/mm3 ) platelet Transient prior therapy relate thrombocytopenia ( &lt; 50,000/mm3 ≤ 30 day prior screen ) acceptable No evidence extramedullary leukemic involvement , exception hepatosplenomegaly BCRABL ratio ≥ 1 % IS accord central laboratory screen examination Prior treatment minimum 2 prior ATPbinding site TKIs ( i.e . imatinib , nilotinib , dasatinib , radotinib ponatinib ) Failure intolerance last previous TKI therapy time screen ( adapted 2013 ELN Guidelines Bacarrani 2013 ) Failure define CMLCP patient ( CP time initiation last therapy ) follow . Patients must meet least 1 follow criterion . Three month initiation therapy : No CHR &gt; 95 % Ph+ metaphases Six month initiation therapy : BCRABL ratio &gt; 10 % IS and/or &gt; 65 % Ph+ metaphases Twelve month initiation therapy : BCRABL ratio &gt; 10 % IS and/or &gt; 35 % Ph+ metaphases At time initiation therapy , loss CHR , CCyR PCyR At time initiation therapy , development new BCRABL mutation At time initiation therapy , confirm loss MMR 2 consecutive test , one must BCRABL ratio ≥ 1 % IS At time initiation therapy , new clonal chromosome abnormality Ph+ cell : CCA/Ph+ Intolerance define : Nonhematologic intolerance : Patients grade 3 4 toxicity therapy , persistent grade 2 toxicity , unresponsive optimal management , include dose adjustment ( unless dose reduction consider best interest patient response already suboptimal ) Hematologic intolerance : Patients grade 3 4 toxicity ( absolute neutrophil count [ ANC ] platelet ) therapy recurrent dose reduction low dos recommend manufacturer Known presence T315I V299L mutation time prior study entry Known second chronic phase CML previous progression AP/BC Previous treatment hematopoietic stemcell transplantation Patient planning undergo allogeneic hematopoietic stem cell transplantation Cardiac cardiac repolarization abnormality , include follow : History within 6 month prior start study treatment myocardial infarction ( MI ) , angina pectoris , coronary artery bypass graft ( CABG ) Clinically significant cardiac arrhythmia ( e.g. , ventricular tachycardia ) , complete leave bundle branch block , highgrade AV block ( e.g. , bifascicular block , Mobitz type II third degree AV block ) QTcF screen ≥450 m ( male patient ) , ≥460 m ( female patient ) Long QT syndrome , family history idiopathic sudden death congenital long QT syndrome , follow : Risk factor Torsades de Pointes ( TdP ) include uncorrected hypokalemia hypomagnesemia , history cardiac failure , history clinically significant/symptomatic bradycardia Concomitant medication ( ) know risk prolong QT interval and/or know cause Torsades de Pointes discontinue replace 7 day prior start study drug safe alternative medication . Inability determine QTcF interval Severe and/or uncontrolled concurrent medical disease opinion investigator could cause unacceptable safety risk compromise compliance protocol ( e.g . uncontrolled diabetes , active uncontrolled infection , pulmonary hypertension ) History acute pancreatitis within 1 year study entry past medical history chronic pancreatitis History acute chronic liver disease Treatment medication meet one follow criterion discontinue least one week prior start treatment study treatment Moderate strong inducer CYP3A Moderate strong inhibitor CYP3A and/or Pgp Substrates CYP3A4/5 , CYP2C8 , CYP2C9 narrow therapeutic index Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 3 day last dose ABL001 . Highly effective contraception method include : Total abstinence ( line prefer usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception Female sterilization ( surgical bilateral oophorectomy ( without hysterectomy ) total hysterectomy tubal ligation least six week take study treatment ) . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment Male sterilization ( least 6 month prior screen ) . The vasectomized male partner sole partner subject . Use oral , injected implant hormonal method contraception placement intrauterine device ( IUD ) intrauterine system ( IUS ) form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception . In case use oral contraception woman stable pill minimum 3 month take study treatment . Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) , total hysterectomy tubal ligation least six week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . Sexually active male unless use condom intercourse take drug treatment 3 day stop treatment father child period . A condom require use also vasectomize men well intercourse male partner order prevent delivery drug via semen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Phase 3</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>bosutinib</keyword>
	<keyword>ABL001</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
	<keyword>Chronic myelogenous leukemia ( CML )</keyword>
	<keyword>chronic myeloid leukemia ( CML )</keyword>
	<keyword>chronic myelocytic leukemia ( CML )</keyword>
	<keyword>chronic granulocytic leukemia ( CGL )</keyword>
	<keyword>cancer white blood cell</keyword>
	<keyword>clonal bone marrow stem cell disorder</keyword>
	<keyword>proliferation mature granulocyte</keyword>
</DOC>